Light gray square, with a dark gray border on the sides.

Blog

The Borderline Case You Can't Afford to Get Wrong: How Advanced Plaque Analysis Changes the Clinical Calculus

May 19, 2026

Part 1 of 5 in Circle's Coronary Plaque series.

Consider a familiar scenario. A 52-year-old presents with atypical chest discomfort. The stress test is borderline. The referring physician is uncertain — is this true coronary disease, or something else? Standard imaging has been done. The anatomy looks, on the surface, mostly normal. And yet something about this patient doesn't sit right.


This is the case where clinicians have historically had to make consequential decisions with incomplete information. Escalate to invasive angiography and risk an unnecessary procedure. De-escalate and risk missing a vulnerable plaque that hasn't yet caused significant stenosis — but will.


Coronary artery disease doesn't announce itself neatly. A substantial share of acute coronary events occur in patients with non-obstructive coronary disease — lesions that would not have triggered revascularization on a standard angiogram. The stenosis grade has always been an imperfect surrogate for risk. What matters is the plaque itself: its composition, its burden, and its vulnerability.


Advanced CCTA plaque analysis changes that calculus.

Beyond Stenosis: What Plaque Characterization Actually Tells You


Coronary CT angiography is already the most guideline-supported non-invasive modality for evaluating stable chest pain. The 2021 ACC/AHA Chest Pain Guidelines elevated CCTA to a Class I recommendation for initial evaluation — a reflection of trial data from SCOT-HEART and PROMISE showing superior diagnostic accuracy and meaningfully better downstream outcomes.


But standard CCTA reporting stops at stenosis. The next frontier is what the plaque looks like — and that requires dedicated post-processing analysis.


High-risk plaque features identified on CCTA carry independent prognostic weight:


  • Low-attenuation plaque (LAP): Lipid-rich necrotic core content associated with plaque vulnerability
  • Positive remodeling: Outward arterial expansion that masks stenosis severity while indicating active plaque development
  • Spotty calcification: Small, isolated calcium deposits correlated with plaque instability
  • Pericoronary adipose tissue (PCAT): A marker of coronary inflammation detectable on standard CCTA datasets


The PARADIGM registry, one of the largest longitudinal CCTA studies, demonstrated that whole-heart plaque burden and progression — not just stenosis — independently predict major adverse cardiovascular events. More recently, 10-year outcomes from SCOT-HEART showed a sustained reduction in coronary heart disease death and non-fatal MI in patients managed with CCTA-guided care, and the ongoing SCOT-HEART 2 trial is now testing CCTA as a primary-prevention screening tool against standard risk scoring.


This is not an emerging research concept. It is becoming a clinical standard — and the gap between sites that can do it and sites that can't is widening.


The Diagnostic Confidence Problem


The challenge for most programs isn't awareness. Cardiologists and radiologists increasingly understand what plaque analysis offers. The challenge is access: most CCTA reporting workflows were built for stenosis assessment and were never designed to support quantitative plaque characterization.


Manual plaque analysis is time-consuming and prone to inter-observer variability. Dedicated standalone tools require separate logins, separate data pipelines, and a workflow that doesn't integrate cleanly with the reading environment clinicians already use. The result is that plaque characterization gets done inconsistently — on selected cases, by certain readers, when time permits.


That inconsistency has consequences. It means the same patient might receive a comprehensive plaque report at one visit and a stenosis-only report at the next. It means risk stratification quality varies by reader and by shift. And it means that the borderline case — the 52-year-old with atypical symptoms and a mostly normal scan — may not get the full picture needed to make a confident call.


What Changes When Plaque Analysis Is Built Into the Workflow


cvi42 integrates CCTA plaque analysis natively within the same post-processing environment used for cardiac MRI, CT function, and structural heart assessment. The result is a materially different clinical experience.


Quantitative plaque metrics — total plaque volume, LAP volume, percent atheroma volume, high-risk plaque feature scoring — are generated within the same workspace where the clinician reviews anatomy, function, and prior studies. There is no separate login, no data export, no switching between applications. The plaque data is part of the report, not appended to it afterward.


For the borderline case, that integration matters. A cardiologist reviewing a CCTA can see, in a single view, that a lesion with 40% stenosis also carries high LAP burden — changing the risk interpretation and supporting a more aggressive preventive management decision. Or the reverse: a case that looks alarming on anatomy shows low-burden, calcified, stable plaque — supporting confident de-escalation and a clear patient conversation.


This is the kind of nuanced, evidence-based characterization that current ACC/AHA prevention guidelines call for. cvi42 makes it achievable in standard clinical workflow, not just in research centers.


From Uncertainty to a Defensible Decision


There is also a medicolegal dimension to this conversation that cardiologists and radiologists are increasingly aware of. Missed plaque diagnoses — particularly in patients who subsequently present with acute coronary syndrome — are among the most scrutinized claims in cardiovascular imaging litigation. A reporting workflow that produces only stenosis data, when AI-assisted plaque characterization was available and guideline-supported, is increasingly difficult to defend.


The standard of care is moving. Adopting a platform that supports guideline-concordant plaque analysis is not just a clinical choice — it is a professional risk management decision.


Putting It Together


Advanced coronary plaque analysis represents one of the most significant advances in non-invasive cardiovascular imaging in the past decade. The clinical evidence is mature. The guidelines are aligned. The technology to do it efficiently, in standard workflow, now exists.


The 52-year-old with the borderline stress test and the atypical symptoms deserves more than a stenosis grade. With cvi42, you have the plaque insights to tell the full story — and the confidence to act on it.


Book a cvi42 demo to see coronary plaque analysis  →


Stay tuned for more on Advanced Plaque Analysis from the perspective of IT and PACS administrators, CFOs and finance leadership, imaging lab directors and department heads.

A medical professional in a navy blue scrub top points to heart scan imagery on a monitor while consulting a colleague.
May 12, 2026
The Effort, Risks, and Why It’s Worth It Quantifying the Effort of a Single Platform Learning a new (or deeper) way of working Even for existing cvi 42 users, full standardization across cardiac imaging means: Adapting to new modules or modalities. Rethinking how you structure reading lists when more work is visible in one place. Helping develop shared templates and protocols. It’s completely normal to see a temporary dip in productivity when something new is introduced. Our brains are wired for loss aversion: we tend to focus more on what we might lose than on what we could gain. Recognizing that bias helps put the slowdown in perspective: it’s not a setback, it’s just part of the process that leads to long‑term progress. 
Secure data within the cvi42 cardiovascular imaging application for AI enabled postprocessing
May 5, 2026
Local Processing for Complete Data Security When cvi 42 processes imaging data, everything takes place within the customer’s secure environment. All image data and derived results are managed locally, whether on a hospital workstation or through a customer-managed server installation. No data is ever transmitted outside the institution. This architecture ensures compliance with strict hospital IT policies and data protection frameworks. For clinical users, this means AI-powered results without any compromise to data privacy or network security. The Circle AI Engine: Trained, Validated, and Frozen “Each of the AI models powering cvi42 is architected and developed within Circle’s controlled research and development environment. Circle’s data science and clinical AI research teams use diverse and representational datasets to train and validate each algorithm. The process typically involves supervised learning, where the AI learns to recognize patterns and structures such as the left ventricle, myocardium, or aortic root by comparing its results to expert-annotated data. Once performance meets clinical and regulatory standards, the AI model is locked, “frozen” and encrypted during its integration within cvi42. This means the model’s behavior is fixed, it does not continue to learn or change once deployed at a customer site. The model you use in cvi 42 is the validated version approved for clinical use, ensuring consistent and reproducible results across all installations. No Learning from Customer Data It is important to clarify: the AI in cvi 42 does not learn from any data processed at the customer site. The algorithm applies its pre-trained parameters to each image set locally. It does not store patient data, send information externally, or modify its internal model based on what it sees or whether a user edits its outputs. Each analysis is isolated, ensuring the AI’s decisions remain consistent and the patient’s information stays protected within the facility’s network. How the AI Analyzes Medical Images At a technical level, cvi42’s AI is a deep learning-based image analysis engine trained to recognize and segment cardiac anatomy on MR and CT images. Primarily using convolutional neural networks, it performs pixel- or voxel-level classification to delineate key structures, including the endocardial and epicardial borders. These segmentations enable the measurements of clinically relevant metrics such as chamber volumes, ejection fraction, and myocardial mass. This process mimics how expert readers would interpret the same dataset, but it happens in seconds and with objective consistency across cases. Designed for Trust, Built for Performance AI in cvi 42 is designed to automate routine analysis while keeping clinicians fully in control. Users can review, adjust, and approve AI-generated contours as needed, ensuring that results always meet their clinical standards. Combined with local data processing, frozen AI models, and Circle’s rigorous training pipeline, this approach delivers accuracy and reliability without ever compromising patient privacy.
A healthcare worker in a white coat juggles colorful balls in a hospital corridor, with staff and a patient nearby.
March 23, 2026
Clinical Wins and Daily Practice Introduction A single cardiovascular imaging platform like Circle’s cvi 42 changes daily work for cardiologists and radiologists from “tool juggling” to focused clinical practice. But it also asks for effort and carries real, though manageable, risks. Seeing this change from your perspective, the people interpreting images and shaping programs, makes it easier to decide whether adopting a unified platform is worthwhile.
Patient in a hospital gown lies on a CT scanner bed, nurse smiles and comforts him. White and gray machine, neutral setting.
March 17, 2026
For years, the Coronary Artery Calcium (CAC) score has been the gold standard for a quick, non-invasive look at heart disease risk. It’s a vital tool that has helped millions of patients understand if they have "hardening of the arteries." But while a calcium score tells us that plaque is present, it only tells part of the story. As medical technology evolves, we are moving beyond simply identifying the presence of calcium to a much more detailed understanding of heart disease. With the advent of AI-enabled coronary plaque analysis, such as cvi42 | Plaque , patients and physicians now have access to a deeper level of insight that was previously impossible to achieve through standard screening alone. What is AI-Enabled Coronary Plaque Analysis? While a traditional calcium score measures the amount of mineralized (hard) plaque in your coronary arteries, AI-enabled plaque analysis looks at the "soft" or non-calcified plaque as well.

Subscribe to our newsletter

 Don’t miss future articles or publications.